AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing Of Claims

1-108. (canceled)

109. (currently amended) A compound consists of a formula selected from the group consisting of the formula

wherein

R₂, R₃, R₄, and R₅ are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, thio, cyano, nitro, and a carbonyl group, each substituted or unsubstituted;

 R_{14} is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R_{14} is a substituent that is convertible in vivo to hydrogen:

M is selected from the group consisting of trifluoroacetyl (-C(O)-CF₃),
-NH-P(O)OH-CH₃, sulfonamides (-SO₂NH₂), hydroxysulfonamides (-SO₂NHOH), thiols(-SH),
and carbonyl groups having the formula -C(O)-R₁₃ wherein R₁₃ is hydroxylamino, hydroxyl,
amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound, wherein the 0-10 atoms are all carbon atoms.

Patent HDAC-5005-C2

110. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of

111. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of

- 112. (currently amended) The compound according to claim 109, wherein R₁₄ is <u>hydrogen</u>. selected from the group consisting of hydrogen and a substituent that is convertible in vivo to hydrogen.
- 113. (previously presented) The compound according to claim 109, wherein R_{14} is a substituted or unsubstituted $C_{1:4}$ alkyl.
- 114. (previously presented) The compound according to claim 109, wherein R₁₄ is a substituted or unsubstituted -C(O)C_{1.6} alkyl.
- 115. (previously presented) The compound according to claim 109, wherein R_{14} is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 116. (previously presented) The compound according to claim 109, wherein at least one of R₂, R₃, R₄, or R₅ is fluoro.

- 117. (canceled)
- 118. (previously presented) The compound according to claim 109, wherein M is selected from the group consisting of:

- 119. (previously presented) The compound according to claim 109, wherein M is a hydroxamic acid moiety.
- 120. (previously presented) The compound according to claim 109, wherein -L-M is

(currently amended) A compound of a formula selected from the group consisting of the formula:

wherein

R₂, R₃, R₄, and R₅ are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, cyano and nitro, each substituted or unsubstituted;

R₁₄ is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl,

heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R₁₄ is a substituent that is convertible in vivo to hydrogen;

M is selected from the group consisting of trifluoroacetyl (-C(O)-CF₃),
-NH-P(O)OH-CH₃, sulfonamides (-SO₂NH₂), hydroxysulfonamides (-SO₂NHOH), thiols(-SH),
and carbonyl groups having the formula -C(O)-R₁₃ wherein R₁₃ is hydroxylamino, hydroxyl,
amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 2-10 atoms separation between the M substituent and the remainder of the compound, wherein the 2-10 atoms are all carbon atoms.

122. (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of

123. (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of

- 124. (currently amended) The compound according to claim 121, wherein R₁₄ is <u>hydrogen</u>. selected from the group consisting of hydrogen and a substituent that is convertible in vivo to hydrogen.
- 125. (previously presented) The compound according to claim 121, wherein R_{14} is a substituted or unsubstituted C_{1-6} alkyl.

- 126. (previously presented) The compound according to claim 121, wherein R₁₄ is a substituted or unsubstituted -C(O)C₁₋₆ alkyl.
- 127. (previously presented) The compound according to claim 121, wherein R_{14} is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 128. (previously presented) The compound according to claim 121, wherein at least one of R₂, R₂, Or R₃ is fluoro.
- 129. (canceled)
- 130. (previously presented) The compound according to claim 121, wherein M is selected from the group consisting of:

- (previously presented) The compound according to claim 121, wherein M is a hydroxamic acid moiety.
- 132. (previously presented) The compound according to claim 121, wherein -L-M is

133. (currently amended) A compound of a formula selected from the group consisting of the formula:

wherein

 R_2 , R_3 , R_4 , and R_5 are each independently selected from the group consisting of hydrogen, halo, (C_{1-10}) alkyl, (C_{1-10}) alkoxy, (C_{5-12}) aryl, (C_{5-12}) heteroaryl, cyano, and nitro, each substituted or unsubstituted:

 R_{14} is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R_{14} is a substituent that is convertible in vivo to hydrogen;

M is selected from the group consisting of

and

L is selected from the group consisting of (E) isomer of –CH=CH-, (Z) isomer or –CH=CH-, and mixtures of (E) and (Z) isomers of –CH=CH-.

134. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of

135. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of

- 136. (currently amended) The compound according to claim 133, wherein R₁₄ is <u>hydrogen</u>. selected from the group consisting of hydrogen and a substituent that is convertible in vivo to hydrogen.
- 137. (previously presented) The compound according to claim 133, wherein R_{14} is a substituted or unsubstituted $C_{1.6}$ alkyl.
- 138. (previously presented) The compound according to claim 133, wherein R_{14} is a substituted or unsubstituted -C(O)C_{1.6} alkyl.
- 139. (previously presented) The compound according to claim 133, wherein R_{14} is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 140. (previously presented) The compound according to claim 133, wherein at least one of R_2 , R_3 , R_4 , or R_5 is fluoro.

141-142. (canceled)

- 143. (previously presented) The compound according to claim 133, wherein M is a hydroxamic acid moiety.
- 144. (previously presented) The compound according to claim 133, wherein -L-M is

145. (previously presented) The compound according to claim 109, wherein M is

146. (previously presented) The compound according to claim 109, wherein M is

147. (previously presented) The compound according to claim 109, wherein M is

148. (previously presented) The compound according to claim 109, wherein M is

149. (previously presented) The compound according to claim 109, wherein M is

150. (previously presented) The compound according to claim 109, wherein M is

151. (previously presented) The compound according to claim 109, wherein M is

152. (previously presented) The compound according to claim 109, wherein M is

153. (previously presented) The compound according to claim 109, wherein M is

154. (previously presented) The compound according to claim 109, wherein M is

155. (previously presented) The compound according to claim 121, wherein M is

156. (previously presented) The compound according to claim 121, wherein M is

157. (previously presented) The compound according to claim 121, wherein M is

158. (previously presented) The compound according to claim 121, wherein M is

159. (previously presented) The compound according to claim 121, wherein M is

160. (previously presented) The compound according to claim 121, wherein M is

161. (previously presented) The compound according to claim 121, wherein M is

162. (previously presented) The compound according to claim 121, wherein M is

163. (previously presented) The compound according to claim 121, wherein M is

164. (previously presented) The compound according to claim 121, wherein M is

165. (previously presented) The compound according to claim 121, wherein M is

166. (previously presented) The compound according to claim 133, wherein M is

167. (previously presented) The compound according to claim 133, wherein M is

168. (previously presented) The compound according to claim 133, wherein M is

169. (previously presented) The compound according to claim 133, wherein M is

170. (previously presented) The compound according to claim 133, wherein M is

171. (previously presented) The compound according to claim 133, wherein M is

172. (previously presented) The compound according to claim 133, wherein M is

173. (previously presented) The compound according to claim 133, wherein M is

174-175. (canceled)

176. (previously presented) The compound according to claim 109, wherein -L-M is

177. (previously presented) The compound according to claim 121, wherein -L-M is